Discovery of AZD3463 as a Novel ALK/IGFR Dual Inhibitor and its Ability in Overcoming Acquired Resistance to Crizotinib. Presented by B Yang at 8th Protein Kinases in Drug Discovery 2013, Boston USA.
Concurrent roles for IGF1R and EGFR in driving acquired resistance to crizotinib and ability to overcome with a combination of the ALK/IGF1R inhibitor AZD3463 and Iressa. Abstr. 4465 presented by L Drew et al. AACR Annual Meeting 2013 Washington DC USA.